Shanghai Fosun Pharmaceutical (02196) plans to participate in the investment to establish a nuclear pharmaceutical business platform company Xing Rui Jing Xuan.

Shanghai Fosun Pharmaceutical (02196) announced that, in order to layout the field of nuclear drug products and further enrich the group's innovative product pipeline, the company (or its holding subsidiaries) intends to participate in the investment establishment of a nuclear drug business platform company called Xing Rui Jing Xuan (the new company). At the same time, in order to fully motivate the company's core team and enhance team cohesion and core competitiveness, the company plans to concurrently implement the follow-up investment during the establishment of the new company, and adopt the initial incentive plan after the establishment of the new company. After the establishment of the new company, it is planned to layout the integrated nuclear drug product track around the field of broad-spectrum tumor diagnosis and treatment through various paths such as self-research and cooperative development.